{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings",
  "queries": [
    "https://consensus.app/search/akkermansia-muciniphila-glycemic-control/og3g0CWlR86FlNlylN1O6g/"
  ],
  "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.",
  "primary_comparison_count": 8,
  "primary_comparisons": [
    {
      "pmid": "31263284",
      "doi": "10.1038/s41591-019-0495-2",
      "source_type": "primary study report",
      "study_group": "MUCT-NCT02637115",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Pilot marker benefit versus clinical glycemia",
      "result_comparison": "Consensus reports improved insulin/HOMA with unchanged fasting glycemia/HbA1c. Selected original Methods and Results independently confirm HOMA calculation, unchanged fasting glycemia and HbA1c, and a not-markedly-hyperglycemic baseline. These clinical nulls do not erase the genuine marker effects or demonstrate ineffectiveness in every population.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/31263284/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\examinations\\original-0-8-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\body-presentation-receipts\\31263284-s0-p0-1-2-3-7-8.json",
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\body-presentation-receipts\\31263284-s7-p3-4-5-9-13-14.json"
      ]
    },
    {
      "pmid": "31263284",
      "doi": "10.1038/s41591-019-0495-2",
      "source_type": "primary study report",
      "study_group": "MUCT-NCT02637115",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Baseline imbalance and analyzed participants",
      "result_comparison": "Consensus identifies 40 enrolled and 32 completers. The original body confirms 11 placebo, 12 pasteurized and nine live completers after personal, antibiotic-use and protocol exclusions, with higher insulin/lower sensitivity in the pasteurized group at baseline. This imbalance and completion analysis limit a definitive clinical interpretation; the provider summary does not replace those Methods details.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/31263284/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\examinations\\original-0-8-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\body-presentation-receipts\\31263284-s0-p0-1-2-3-7-8.json",
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\body-presentation-receipts\\31263284-s7-p3-4-5-9-13-14.json"
      ]
    },
    {
      "pmid": "42343233",
      "doi": "10.1080/19490976.2026.2690689",
      "source_type": "primary study report",
      "study_group": "MUCT-NCT05114018",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Larger trial primary null and exploratory scope",
      "result_comparison": "Consensus describes the 142-person trial primary Matsuda null with subsequent low-baseline marker signals. The examined original abstract confirms the intention-to-treat primary null and labels subsequent analyses exploratory, including weight P=.06 in low-baseline participants. We did not obtain its complete Methods/Results through the attempted public route, so detailed recruitment disruptions and full analysis-plan claims in the provider are not treated as independently verified body findings.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/42343233/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\examinations\\original-0-8-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "42120725",
      "doi": "10.1038/s41591-026-04394-7",
      "source_type": "primary study report",
      "study_group": "MUCT-NCT05417360",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Genuine product-specific weight-maintenance benefit",
      "result_comparison": "Consensus correctly preserves lower 24-week regain after an eight-week diet lead-in. The original abstract confirms 90 participants, the maintenance outcome and lower regain with MucT than placebo. This is openly scored as supplemental SC5 added after discovery; the primary glycemic/function gate remains unchanged. Pre-maintenance lead-in eligibility precedes assessed regain and does not exclude later regain failures retrospectively.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/42120725/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\examinations\\original-0-8-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "39683431",
      "doi": "10.3390/nu16234037",
      "source_type": "primary study report",
      "study_group": "PMID39683431",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Different-strain function and absence of measurement",
      "result_comparison": "The provider says direct human trials show no measurable physical-function gains while citing MucT metabolic/maintenance studies and does not use HB05 as a named supporting anchor. A missing endpoint is not a tested null. Our selected HB05 original Methods/Results show a different strain in older adults, positive left/combined extensor torque, unchanged grip and myostatin, and per-protocol analysis. Those positives remain real but cannot be extrapolated to MucT clinical metabolism.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/39683431/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\examinations\\original-0-8-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\body-presentation-receipts\\39683431-s1-p1-2-3-5.json",
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\body-presentation-receipts\\39683431-s2-p0-2-3-4-5.json"
      ]
    },
    {
      "pmid": "32675291",
      "doi": "10.1136/bmjdrc-2020-001319",
      "source_type": "primary study report",
      "study_group": "WBF-NCT03893422",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Review-mediated mixture statement checked against its original",
      "result_comparison": "Consensus supports its multi-strain glucose/HbA1c statement through review/mechanism citations. Our examined WBF-011 original instead supplies the direct 76-person 12-week trial: the five-strain/inulin mixture improves postprandial glucose and reports a HbA1c signal. This specific product evidence cannot isolate Akkermansia component necessity or validate other commercial formulas. Reviews do not add primary-count credit.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/32675291/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\examinations\\original-38-46-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "39879980",
      "doi": "10.1016/j.cmet.2024.12.010",
      "source_type": "primary study report",
      "study_group": "WST01-NCT04797442",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Live strain full-population null versus baseline subgroup",
      "result_comparison": "Consensus separates live WST01 from pasteurized MucT. The original 58-person 12-week trial abstract confirms no overall HbA1c/weight advantage and low-baseline colonization/clinical signals. Baseline abundance is measurable before outcomes, but exploratory subgroup and within-group significance cannot automatically establish a prospective replicated treatment interaction.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/39879980/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\examinations\\original-38-46-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "40451504",
      "doi": "10.1016/j.clnesp.2025.05.045",
      "source_type": "primary study report",
      "study_group": "PMID40451504",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Yogurt endpoints and untested physical fitness",
      "result_comparison": "Consensus reports selected postbiotic-yogurt anthropometric benefits and says physical fitness was not altered. The original abstract reports waist, fat, AST and appetite comparisons over eight weeks, without a documented physical-fitness contrast. We preserve its product-specific positive endpoints and treat physical function as not established from the examined record, rather than infer a measured null.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/40451504/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\examinations\\original-46-54-10000.json"
      ],
      "body_receipts": []
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\akkermansia-metabolic-health\\consensus-browser-2026-10-13.json",
      "sha256": "6fcd4f1a47bdb15df8beb222a435eb74eb982a8f1102456d3d2bc59d0415b48f"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-13",
  "completed_utc": "2026-10-13T17:02:52.660088+00:00",
  "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
}